Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 13.55 is 28% below its 5-year average of 18.72, near the low end of its 5-year range (3.63–48.96).
As of the fiscal period ended Tuesday, June 30, 2026. 5.10% below its 12-month average of 14.28.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 13.55.
CURRENT RATIO
13.55
CURRENT RATIO AVG TTM
14.28
CURRENT RATIO AVG 3Y
15.97
CURRENT RATIO AVG 5Y
18.72
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-5.10%
CURRENT VS 3Y AVG
-15.14%
CURRENT VS 5Y AVG
-27.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.47
median of 675 covered companies
CURRENT VS SECTOR MEDIAN
+290.59%
vs the sector median at left
LENZ Therapeutics, Inc.
Market Cap
$118.80M
Current Ratio
13.55
TTM Avg
14.28
3Y Avg
15.97
5Y Avg
18.72
Market Cap
$118.02M
Current Ratio
2.00
TTM Avg
1.45
3Y Avg
1.62
5Y Avg
1.71
Market Cap
$117.53M
Current Ratio
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$121.00M
Current Ratio
0.18
TTM Avg
2.23
3Y Avg
2.69
5Y Avg
2.63
Market Cap
$114.74M
Current Ratio
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$116.00M
Current Ratio
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$122.59M
Current Ratio
10.21
TTM Avg
11.59
3Y Avg
10.00
5Y Avg
8.96
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.80M | 13.55 | 14.28 | 15.97 | 18.72 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.02M | 2.00 | 1.45 | 1.62 | 1.71 |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | 6.49 | 6.44 | 8.52 | 8.53 |
| Genelux Corporation (GNLX)vs › | $116.36M | 2.39 | 3.50 | 2.69 | 1.97 |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.00M | 0.18 | 2.23 | 2.69 | 2.63 |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.99M | 1.33 | 1.19 | 1.50 | 3.26 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $114.74M | 3.36 | 3.23 | 4.24 | 6.08 |
| Coya Therapeutics, Inc. (COYA)vs › | $116.00M | 13.40 | 10.04 | 7.53 | 8.95 |
| enGene Holdings Inc. (ENGN)vs › | $122.59M | 10.21 | 11.59 | 10.00 | 8.96 |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | 12.26 | 9.59 | 11.55 | 11.23 |
Current Ratio
13.55
Quick Ratio
13.31
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 13.55 |
| 2026-03-31 | 10.40 |
| 2025-12-31 | 14.23 |
| 2025-09-30 | 12.69 |
| 2025-06-30 | 20.54 |
| 2025-03-31 | 23.09 |
| 2024-12-31 | 20.36 |
| 2024-09-30 | 28.63 |
| 2024-06-30 | 23.23 |
| 2024-03-31 | 11.47 |
| 2023-12-31 | 3.63 |
| 2023-09-30 | 5.34 |
| 2023-06-30 | 20.47 |
| 2023-03-31 | 18.85 |
| 2022-12-31 | 4.91 |
| 2022-09-30 | 22.07 |
| 2022-06-30 | 27.07 |
| 2022-03-31 | 26.93 |
| 2021-12-31 | 31.44 |
| 2021-09-30 | 35.60 |
| 2021-06-30 | 48.96 |
| 2021-03-31 | 28.20 |
| 2020-12-31 | 0.66 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
